Valinor Discovery

Valinor Discovery is a New York-based biotechnology company focused on the development of next-generation precision medicines for oncology. The company was founded by a team of veteran drug developers with a track record of success at Loxo Oncology, specializing in structure-based drug design and medicinal chemistry. Valinor's primary mission is to create highly selective small molecule inhibitors that address acquired resistance in genetically defined cancers. By targeting well-understood but difficult-to-drug kinases, the company aims to deliver best-in-class therapies for patients with limited treatment options. Valinor is currently advancing its internal pipeline through the pre-clinical stage and is backed by prominent life science investors.